Evidence map›Paper›PMID 39594640›Full record

ArticleCells2024

Multicellular Cancer-Stroma Spheres (CSS) for In Vitro Assessment of CAR-T Cell-Associated Toxicity.

Aigul R Rakhmatullina, Mariya A Zolotykh, Yuliya V Filina, Aigul Kh Valiullina, Ekaterina A Zmievskaya, Dina U Gafurbaeva, Aisylu R Sagdeeva, Emil R Bulatov, Albert A Rizvanov, Regina R Miftakhova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aigul R RakhmatullinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Mariya A ZolotykhInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0003-2473-5514
Yuliya V FilinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-1853-8365
Aigul Kh ValiullinaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Ekaterina A ZmievskayaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Dina U GafurbaevaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Aisylu R SagdeevaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-9318-2004
Emil R BulatovInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0003-2961-0032
Albert A RizvanovInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-9427-5739
Regina R MiftakhovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.ORCID 0000-0002-6686-1968

Funding

This work was funded by the subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities FZSM-2022-0016
6 · The paper itself

Abstract

CAR-T therapy has revolutionized the field of oncology, offering a promising treatment option for cancer patients. However, the significant morbidity associated with therapy-related toxicity presents a major challenge to its widespread use. Despite extensive research into the underlying mechanisms of CAR-T therapy-related toxicity, there are still many unknowns. Furthermore, the lack of adequate in vitro models for assessing immunotoxicity and neurotoxicity further complicates the development of safer cellular therapies. Previously in our laboratory, we developed cancer-stroma spheres (CSS) composed of prostate adenocarcinoma PC3 cells and mesenchymal stem cells (MSC). Herein we present evidence that multicellular CSS could serve as a valuable in vitro model for toxicity studies related to CAR-T therapy. CSS containing CD19-overexpressing PC3M cells exhibited increased secretion of CAR-T cell toxicity-associated IL-8, MCP-1, and IP-10 in the presence of anti-CD19 CAR-T cells, compared to spheres derived from single cell types.

Indexed as

Spheroids, CellularAntigens, CD19Cell Line, TumorHumansImmunotherapy, AdoptiveMaleMesenchymal Stem CellsPC-3 CellsProstatic NeoplasmsReceptors, Chimeric AntigenStromal CellsAntigens, CD19Receptors, Chimeric Antigencancer-stroma spheresCAR-T therapycytokine release syndromeIL-8immune effector cell-associated neurotoxicity syndromeIP-10MCP-1mesenchymal stem cell

Identifiers

PMID39594640
PMCPMC11593285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.